CD4+/CD56+ hematodermic neoplasm
CD4+/CD56+ hematodermic neoplasm
Explore linked clinical trials. Standard reference: MONDO:001946721 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | B-cell neoplasm, Burkitt Leukemia, Burkitt lymphoma, CD4+/CD56+ hematodermic neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Epstein-Barr virus infection, GATA2 deficiency with susceptibility to MDS/AML, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, Tumor Virus Infections, acute biphenotypic leukemia, acute leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, acute undifferentiated leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hereditary disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mast cell leukemia, mastocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts-1, myeloid leukemia, myeloproliferative neoplasm, neoplasm, skin disorder, skin neoplasm, viral infectious disease | Active, not recruiting | Phase 2 | 2026-09-25 | NCT03779854 | |
| A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-09-15 | NCT07785180 | |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | B-cell neoplasm, Burkitt Leukemia, Burkitt lymphoma, CD4+/CD56+ hematodermic neoplasm, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, Tumor Virus Infections, acute biphenotypic leukemia, acute leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, acute undifferentiated leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mast cell leukemia, mastocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm, viral infectious disease | Not yet recruiting | Phase 2 | 2026-09-14 | NCT07819396 | |
| CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Early phase 1 | 2026-09-14 | NCT06765876 | |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-09-14 | NCT04216524 | |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | CD4+/CD56+ hematodermic neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Skin and Connective Tissue Diseases, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, myeloid leukemia, myeloproliferative neoplasm, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-04 | NCT03386513 | |
| Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-08-28 | NCT06690827 | |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, acute biphenotypic leukemia, acute myeloid leukemia, adult acute lymphoblastic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, myeloid leukemia, neoplasm, skin disorder, skin neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-08-26 | NCT02159495 | |
| A Registry-study of ELZONRIS in Participants With BPDCN | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-08-25 | NCT07785154 | |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, acute leukemia, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 | 2026-08-14 | NCT04013685 | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, acute myeloid leukemia, aggressive systemic mastocytosis, bone marrow disorder, classic Hodgkin lymphoma, connective tissue neoplasm, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mastocytosis, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 | 2026-07-28 | NCT05362773 | |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, myeloid leukemia, myeloproliferative neoplasm, neoplasm, non-Hodgkin lymphoma, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-07-22 | NCT06013423 | |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients | CD4+/CD56+ hematodermic neoplasm, Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-07-01 | NCT07007052 | |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-06-17 | NCT03113643 | |
| Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-06-05 | NCT05430971 | |
| CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-05-19 | NCT04318678 | |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | CD4+/CD56+ hematodermic neoplasm, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, acute biphenotypic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, juvenile myelomonocytic leukemia, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-05-18 | NCT03326921 | |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, CD4+/CD56+ hematodermic neoplasm, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, T-lymphoblastic lymphoma, Tumor Virus Infections, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mature T-cell and NK-cell non-Hodgkin lymphoma, monoclonal gammopathy, myeloid leukemia, neoplasm, plasma cell leukemia, plasma cell neoplasm, skin disorder, skin neoplasm, vascular disorder, vascular hemostatic disease, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-04-13 | NCT07523555 | |
| SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Blood Protein Disorders, CD4+/CD56+ hematodermic neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, acute biphenotypic leukemia, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, monoclonal gammopathy, myeloid leukemia, neoplasm, plasma cell neoplasm, skin disorder, skin neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-02-12 | NCT06325748 | |
| Q702 for the Treatment of Patients With Hematologic Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Erdheim-Chester disease, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, bone marrow disorder, cardiovascular disorder, chronic myelomonocytic leukemia, follicular lymphoma, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, histiocytic sarcoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, interstitial lung disease, leukemia, lung disorder, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, monoclonal gammopathy, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, non-Langerhans cell histiocytosis, peripheral T-cell lymphoma, not otherwise specified, plasma cell neoplasm, primary central nervous system lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, respiratory system disorder, skin disorder, skin neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2025-10-10 | NCT06712810 | |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | B-cell neoplasm, CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, acute biphenotypic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2024-12-06 | NCT05476770 |